Member Info for crumbs

One day the horse will bolt....But who will be on the horse??

Modified being moditope....One day predictive text will recognise it as a word??

Of scancells IP is quite extraordinary when you think about it....A pipeline of 3 platforms each one novel with game changing potential but modified being a potential big pharma of a platform all by itself....No way is this being overlooked IMHO....The ones we need to be interested have got to be interested...Is there a comparable share out there?

It is entirely possible they do not feel the need as they know what is coming and investor sentiment is not a very high priority at this moment in time... I dunno but like you would prefer they did make a but more effort in that area.. sure CH does answer emails and that is good but really that's to existing holders who are usually having kittens over sp it is not attracting new pi

All depends on how potent the moditope mechanism is in patients... but the mechanism has been proven to exist.

Yeah he was approach about using it as a checkpoint inhibitor combo... 100% survival means there is no need for it to be trialled as a combo no point doing the pre clinical combo experiments... 100% can not be improved on:)...however once trial results are in we will know if there will be a need to add other therapies and what they may best be.... remember now there is modi2 there can be all kinds of moditope cocktail combos!...

With arrival of modi2 scancell can target more than the already very impressive 17 cancer targets...

'Scancell believes this second mechanism of action has the potential to broaden the utilisation of the Moditope® platform.

Modi-2 is currently in pre-clinical development and work is underway to characterise specific homocitrullinated peptides for clinical development that have the potential to address different cancer indications to Modi-1, including tumours with a particularly immunosuppressive environment.'

Potential commercial values are HUGE

They do not 'need' to... the point is such facts can attract new investment...

A quickly cobbled together RNS I would say and probably in no small part due to investor pressure... no comment from Lindy on this one though she did on Euro patent.. but then again she is too busy replying to emails or not lol ...scancell could totally jazz up their RNS's but never do we still are much in dark about Glycans.. though there is the word 'commercial' and we know there are valuations around them in excess of £1 billion a year.. yet such info never gets into RNS's... modi1 capable of targeting 17 cancer types.. that is massive! 17 potential target deals on one product... never makes it into the RNS's.... as ever I'm sure ( well sarcomas being replaced by head and neck proves it) there is loads going on behind the scenes we do not know about and for sure as far as pharma and biotech are concerned scancell are behind no cloaks... they are aware... multiple moditope partnership talks... TCR from BioNtech Sahin very exciited by moditope and Mellman of Genentech/Roche too... next RNS now please :)

Nah your still well ahead... I'm heading towards 180k... to be honest, I'm happy with the amount I hold because my intention has always been to hold for full value to come which will be a few years yet(if ever!) it is just about getting average down now... but for sure I am gladly accepting of any 'transformational' newsflow scancell feel able to throw at us lol...

Yeah they won't be all sells... been the same for a few days now... all my recent buys shown as sells..

https://www.proactiveinvestors.co.uk/news/details/216814/scancell-strengthens-ip-with-two-important-patent-grants-in-us-and-europe-216814.html

As RG tweets... 'another brick in the wall'

Yes, smoking and alcohol are major causes of it... RG recently been in China...an no I'm not teaming ramping lol just a little speculation to the change that is all... scancell probably will not at this stage be forthcoming on the reasons for the change..

Can target potentially at least 17 cancer types:

? Breast
? Prostate
? Ovarian
? Cervical
? Endometrial
? Head and neck
? Thyroid
? Glioma
? Lung
? Melanoma
? Skin
? Testis
? Urothelial
? Renal
? Stomach
? Pancreatic
? Liver

We know Triple Breast and Ovarian have been the targets LD has been most keen on from the beginning for her own reasons... these are devastating cancers that often cut the lives of young women short... originally Endometrial cancer was to be a first in trial modi1 target too... later dropped for sarcomas... Vimentin and enolase targets are highly expressed in Sarcomas (100%) so a great target but now replaced....

though have found this : Many epithelial tumours (e.g., thyroid, nasopharyngeal, melanoma) switch from cytokeratin
to vimentin expression during metastasis (EMT transition) or on stem cells

So considering nasopharyngeal cancer is in Southeast China and Taiwan, the most common cause of death in young men. That might be the reason behind the change... but who knows till we knows!

Yes, I would say that one was a sell and everything 5.5 a buy... know mine was :)

From wikipedia:

'In Southeast China and Taiwan, head and neck cancer, specifically nasopharyngeal cancer is the most common cause of death in young men'

In fact as of Feb in our change of auditor RNS... still sarcomas

'Modi-1 is being developed for the treatment of triple negative breast cancer, ovarian cancer and sarcomas.'

Well the last presentation which was Nov 2018 still has 'sarcomas'... so head and neck has only just appeared now there has to be a reason for that and it could well be further lab work has concluded that to be a much better target or someone has wanted that target though if so that is very late seeing as how close to clinic modi1 now is... as far as I know head and neck cancer covers a few kinds? as does sarcomas in fact

It has been 'sarcomas' now it becomes 'head and neck cancer'

Seems something has been going on... wonder if that something has been with someone else involved too.

'The Company also today announces the grant of European patent number 3,063,160 relating to FG88 a monoclonal antibody directed to tumour associated glycans, further strengthening the COMMERCIAL positioning of Scancell's monoclonal antibody development programme.'

Is worth note too... Ruck still didn't use his formula on the figures given by Nottingham to potential £1-2 billion value a year in sales of just 2 Glycan MaBs .....